UBS Maintains Buy on AdaptHealth, Lowers Price Target to $9

Benzinga · 2d ago
UBS analyst Kevin Caliendo maintains AdaptHealth (NASDAQ:AHCO) with a Buy and lowers the price target from $10 to $9.